Sign up now to receive our regular news briefs.

Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,'” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.


  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition. Comments written in all caps will be deleted.

Current day month ye@r *


  • Arts and Culture Features Opinion Playwrite Iddo Netanyahu: ‘Hitler Always Talked About Peace’ (INTERVIEW)

    Playwrite Iddo Netanyahu: ‘Hitler Always Talked About Peace’ (INTERVIEW)

    Late Friday night, on November 13, I was headed for bed when an ominous news bulletin flashed across my computer screen – something about a shooting in Paris. It wasn’t long before the “small number” of shootings and casualties began to double and triple and quadruple. The locations of attacks seemed crazily disorganized, and the tweets and videos became more and more horrifying. It was a long night for many stunned observers. We tried to understand what was happening, and […]

    Read more →
  • Israel Theater BDS Gives Belgian-Jewish Actress New Lease on Life in Tel Aviv

    BDS Gives Belgian-Jewish Actress New Lease on Life in Tel Aviv

    In an interview with the Israeli site nrg on Wednesday, Belgian-Jewish stage actress Noemi Schlosser recounted immigrating to Israel after her career in Europe was destroyed by BDS. Schlosser said she had enjoyed success in Belgium and international acclaim until she was targeted by the Boycott, Divestment and Sanctions movement for her pro-Israel stance during Operation Protective Edge — last summer’s war against Hamas in Gaza. She described watching the theaters where she performed go from packed to nearly empty over a short period of […]

    Read more →
  • Israel Sports In Israel for Champions League Soccer Match, Chelsea Manager Says Team Not Worried About Security Situation

    In Israel for Champions League Soccer Match, Chelsea Manager Says Team Not Worried About Security Situation

    The manager of the Chelsea Football Club said on Monday that he is looking forward to playing in Israel this week against Maccabi Tel Aviv, in spite of the security situation, Israeli news site nrg reported. Jose Murinho, who is already in Israel with his team to compete against Maccabi in the Champions League soccer match, was  asked whether he was worried about the current wave of Palestinian violence sweeping the country. “I have no worries at all regarding the security situation, and neither do […]

    Read more →
  • Book Reviews Opinion In the Middle East, ‘The Tail Wags the Dog’ (REVIEW)

    In the Middle East, ‘The Tail Wags the Dog’ (REVIEW)

    Blaming the West has become the most pervasive method of teaching for many Middle East studies departments, which are becoming the heart of pop-culture academia. Efraim Karsh, a distinguished professor of Middle Eastern studies at Bar-Ilan University and professor emeritus at King’s College London, in his latest book The Tail Wags the Dog: International Politics and the Middle East, dispels this myth. “Britain’s ‘original sin,’ if such was indeed committed, lay not in the breaking up of Middle Eastern unity but […]

    Read more →
  • Features Spirituality/Tradition With Popularity and Sales up, ‘Mensch on a Bench’ Has Much to Smile About

    With Popularity and Sales up, ‘Mensch on a Bench’ Has Much to Smile About – The Mensch on a Bench is so much happier now than he was a year ago. Look carefully and you will notice that, whereas the previous Mensch had a decidedly worried look, this latest version of the popular Hanukkah toy is flashing an exuberant grin. Is the erstwhile Mensch smiling because he expects to be in some 100,000 homes by year’s end? In truth, the change in visage was suggested last year by the “sharks” on ABC’s Shark Tank […]

    Read more →
  • Music US & Canada Adam Sandler Updates Famous ‘Chanukah Song,’ Includes Hulk Hogan, David Beckham and Scarlett Johansson in Latest Version

    Adam Sandler Updates Famous ‘Chanukah Song,’ Includes Hulk Hogan, David Beckham and Scarlett Johansson in Latest Version

    Actor Adam Sandler unveiled a new version of his famous “Chanukah Song” on Saturday, adding a slew of Jewish celebrities to the ditty’s updated lyrics. The comedian — who released the original song about being Jewish during Christmas in 1996 — performed the latest version of the comedic track during the New York Comedy Festival at Carnegie Hall. Marvel Comics creator Stan Lee, actor Jake Gyllenhaal and “the two guys who founded Google” are among the famous Jewish celebrities now in the line up. Sandler also included lyrics about Star Wars‘ Princess […]

    Read more →
  • Music US & Canada Famed Israeli Violinist Itzhak Perlman to Receive Presidential Medal of Freedom

    Famed Israeli Violinist Itzhak Perlman to Receive Presidential Medal of Freedom – Famed Israeli violinist Itzhak Perlman will be among the 17 recipients of America’s Presidential Medal of Freedom next week. He is the fourth Israeli to receive the highest civilian honor in the US. “A native of Israel, he came to the United States at a young age and was introduced to Americans broadly when he appeared on the ‘Ed Sullivan Show’ in 1958. Mr. Perlman made his Carnegie Hall debut in 1963 when he was 18,” a White House […]

    Read more →
  • Features Spirituality/Tradition Don’t Think Israel is a Luxury Destination? Check Out These 6 Spots

    Don’t Think Israel is a Luxury Destination? Check Out These 6 Spots – While Israel is a common destination for cultural and religious pilgrimages, travelers seeking the best hotels, fine dining, and upscale relaxation less often find themselves in the Holy Land. Yet in recent years, the country’s burgeoning tech scene has attracted a business crowd accustomed to ritzy accommodation. Besides, the permanent summer of Tel Aviv and Eilat makes them prime destinations for European vacationers. Israel’s populace managed to tame the swamps and irrigate the desert — so going luxury should […]

    Read more →